Cargando…

First results of a ferritin‐based blood donor deferral policy in the Netherlands

BACKGROUND: Whole blood donors are at risk of becoming iron deficient. To monitor iron stores, Sanquin implemented a new deferral policy based on ferritin levels, in addition to the traditional hemoglobin measurements. METHODS: Ferritin levels are determined in every fifth donation, as well as in al...

Descripción completa

Detalles Bibliográficos
Autores principales: Vinkenoog, Marieke, van den Hurk, Katja, van Kraaij, Marian, van Leeuwen, Matthijs, Janssen, Mart P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496980/
https://www.ncbi.nlm.nih.gov/pubmed/32533600
http://dx.doi.org/10.1111/trf.15906
_version_ 1783583218213060608
author Vinkenoog, Marieke
van den Hurk, Katja
van Kraaij, Marian
van Leeuwen, Matthijs
Janssen, Mart P.
author_facet Vinkenoog, Marieke
van den Hurk, Katja
van Kraaij, Marian
van Leeuwen, Matthijs
Janssen, Mart P.
author_sort Vinkenoog, Marieke
collection PubMed
description BACKGROUND: Whole blood donors are at risk of becoming iron deficient. To monitor iron stores, Sanquin implemented a new deferral policy based on ferritin levels, in addition to the traditional hemoglobin measurements. METHODS: Ferritin levels are determined in every fifth donation, as well as in all first‐time donors. Donors with ferritin levels <15 ng/mL (WHO threshold) are deferred for 12 months; those ≥15 and ≤30 ng/mL for 6 months. The first results were analyzed and are presented here. RESULTS: The results show that 25% of women (N = 20151, 95% CI 24%‐25%) and 1.6% of men (N = 10391, 95% CI 1.4%‐1.8%) have ferritin levels ≤30 ng/mL at their first blood center visit. For repeat (non‐first‐time) donors, these proportions are higher: 53% of women (N = 28329, 95% CI 52%‐54%) and 42% of men (N = 31089, 95% CI 41%‐43%). After a 6‐month deferral, in 88% of returning women (N = 3059, 95% CI 87%‐89%) and 99% of returning men (N = 3736, 95% CI 98%‐99%) ferritin levels were ≥15 ng/mL. After a 12‐month deferral, in 74% of returning women (N = 486, 95% CI 70%‐78%) and 95% of returning men (N = 479, 95% CI 94%‐97%) ferritin levels increased to ≥15 ng/mL. CONCLUSION: Deferral of donors whose pre‐donation ferritin levels were ≤30 ng/mL might prevent donors from returning with ferritin levels <15 ng/mL. This policy is promising to mitigate effects of repeated donations on iron stores.
format Online
Article
Text
id pubmed-7496980
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-74969802020-09-25 First results of a ferritin‐based blood donor deferral policy in the Netherlands Vinkenoog, Marieke van den Hurk, Katja van Kraaij, Marian van Leeuwen, Matthijs Janssen, Mart P. Transfusion Blood Donors and Blood Collection BACKGROUND: Whole blood donors are at risk of becoming iron deficient. To monitor iron stores, Sanquin implemented a new deferral policy based on ferritin levels, in addition to the traditional hemoglobin measurements. METHODS: Ferritin levels are determined in every fifth donation, as well as in all first‐time donors. Donors with ferritin levels <15 ng/mL (WHO threshold) are deferred for 12 months; those ≥15 and ≤30 ng/mL for 6 months. The first results were analyzed and are presented here. RESULTS: The results show that 25% of women (N = 20151, 95% CI 24%‐25%) and 1.6% of men (N = 10391, 95% CI 1.4%‐1.8%) have ferritin levels ≤30 ng/mL at their first blood center visit. For repeat (non‐first‐time) donors, these proportions are higher: 53% of women (N = 28329, 95% CI 52%‐54%) and 42% of men (N = 31089, 95% CI 41%‐43%). After a 6‐month deferral, in 88% of returning women (N = 3059, 95% CI 87%‐89%) and 99% of returning men (N = 3736, 95% CI 98%‐99%) ferritin levels were ≥15 ng/mL. After a 12‐month deferral, in 74% of returning women (N = 486, 95% CI 70%‐78%) and 95% of returning men (N = 479, 95% CI 94%‐97%) ferritin levels increased to ≥15 ng/mL. CONCLUSION: Deferral of donors whose pre‐donation ferritin levels were ≤30 ng/mL might prevent donors from returning with ferritin levels <15 ng/mL. This policy is promising to mitigate effects of repeated donations on iron stores. John Wiley & Sons, Inc. 2020-06-13 2020-08 /pmc/articles/PMC7496980/ /pubmed/32533600 http://dx.doi.org/10.1111/trf.15906 Text en © 2020 The Authors. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Blood Donors and Blood Collection
Vinkenoog, Marieke
van den Hurk, Katja
van Kraaij, Marian
van Leeuwen, Matthijs
Janssen, Mart P.
First results of a ferritin‐based blood donor deferral policy in the Netherlands
title First results of a ferritin‐based blood donor deferral policy in the Netherlands
title_full First results of a ferritin‐based blood donor deferral policy in the Netherlands
title_fullStr First results of a ferritin‐based blood donor deferral policy in the Netherlands
title_full_unstemmed First results of a ferritin‐based blood donor deferral policy in the Netherlands
title_short First results of a ferritin‐based blood donor deferral policy in the Netherlands
title_sort first results of a ferritin‐based blood donor deferral policy in the netherlands
topic Blood Donors and Blood Collection
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496980/
https://www.ncbi.nlm.nih.gov/pubmed/32533600
http://dx.doi.org/10.1111/trf.15906
work_keys_str_mv AT vinkenoogmarieke firstresultsofaferritinbasedblooddonordeferralpolicyinthenetherlands
AT vandenhurkkatja firstresultsofaferritinbasedblooddonordeferralpolicyinthenetherlands
AT vankraaijmarian firstresultsofaferritinbasedblooddonordeferralpolicyinthenetherlands
AT vanleeuwenmatthijs firstresultsofaferritinbasedblooddonordeferralpolicyinthenetherlands
AT janssenmartp firstresultsofaferritinbasedblooddonordeferralpolicyinthenetherlands